Stem-cell approaches for POI and low ovarian reserve are being studied, but nobody should treat them as established fertility treatments. Current international POI guidance flatly states that no intervention has been reliably shown to increase ovarian activity and natural conception rates.[1]
POI, diminished ovarian reserve and poor ovarian response are related but different. Mixing them up can make a study result look more relevant than it really is.
Current guideline criteria include irregular or absent spontaneous cycles for at least 4 months plus FSH above 25 IU/L. A repeat FSH after 4 to 6 weeks is used when the diagnosis is uncertain. AMH is not the primary diagnostic test.[1]
AMH and antral follicle count are useful for estimating ovarian reserve and expected oocyte yield. They are much weaker independent predictors of egg quality, pregnancy and live birth.[3]
This describes a poor response during ovarian stimulation. A trial in poor responders should not automatically be used as evidence for a patient with established POI.
If previously regular periods stop for more than 3 months, or irregular periods stop for 6 months, medical evaluation is recommended. Pregnancy, thyroid disease, prolactin disorders, hypothalamic causes and POI are among the conditions that may need to be separated.[4]
TSH, bone density by DXA where available, lipid profile and diabetes screening.[1]
At least blood pressure, weight and smoking status should be reviewed.[1]
DXA reassessment is recommended when low bone density or osteoporosis is present, based on individual risk.[1]
If TSH is normal, guideline follow-up is every 5 years or sooner when symptoms arise.[1]
Current guidance recommends chromosomal analysis and FMR1 premutation testing. Additional genetic testing may be discussed after genetic counselling.[1]
21-hydroxylase autoantibody screening is recommended. A positive result should lead to adrenal-function assessment by an endocrinologist.[1]
POI is also linked with bone and cardiovascular risk. Current guidance recommends hormone therapy until the usual age of menopause for primary prevention unless an individual contraindication changes the plan.[1]
The 2025 systematic review found that 77.8% of included studies lacked control groups—and 7 to 12 months was the most common follow-up window. The authors called for larger trials and standardized protocols.[5]
These are descriptive totals pooled from different study designs, not a randomized head-to-head estimate. In the same review, 85.2% of studies used autologous cells and 70.3% used intraovarian delivery, showing that “stem-cell treatment” was not one standardized protocol. Do not read the pooled pregnancy counts as your personal probability of pregnancy.[5]
9 women. Three dose groups received 5, 10 or 15 million cells into one ovary. The study was non-randomized and primarily assessed safety, feasibility and dose.
Four of nine participants resumed menstruation. With no control group and only nine participants, this cannot establish a reliable fertility benefit. [6]
15 treated participants were compared with 16 receiving routine ICSI. This population was poor ovarian responders, not a pure POI group.
The paper reported clinical pregnancy in 7 of 15 treated participants and 2 of 16 controls, with 5 versus 1 live births. The sample was small and should not be generalized to every diagnosis. [7]
145 women with POR, DOR or POI were included. This was a retrospective combined protocol, not a randomized trial of one isolated stem-cell treatment.
The study reported 68.28% meeting its defined ovarian-activation endpoint; the abstract reported 7.07% spontaneous gestation and 14.14% pregnancy after IVF. Activation was based on AFC and/or AMH change, not live birth. [8]
A 2025 BMJ Open protocol plans to compare autologous fat-derived stromal vascular fraction (SVF) plus assisted reproduction with assisted reproduction alone in women with POI. Its design shows the level of evidence still needed before benefit can be considered established.[11]
When you compare an offer with a study, ask for the exact endpoint, denominator and follow-up period.
POI and DOR are not evaluated by patient survival. For fertility, the more meaningful endpoints are oocyte retrieval, usable embryos, ongoing pregnancy and live birth.
Can help describe ovarian reserve or expected oocyte yield. They do not prove restored fertility.[3]
Cycle return is relevant, but it does not confirm ovulation, egg quality or pregnancy.
Ask how many participants reached retrieval and how many oocytes were mature, not only how many follicles were seen.
Confirm whether the number means biochemical, clinical or ongoing pregnancy and whether IVF was used.
This is the clearest reproductive endpoint, but current cellular-therapy datasets remain too small and heterogeneous for a universal rate.
“Stem cell” isn’t a complete product description. The cell source, processing, dose, sterility testing, administration route and follow-up all matter.
The right parallel plan depends on whether your priority is fertility, low-estrogen symptoms, long-term health or fertility preservation before gonadotoxic treatment.
Ovarian activity can sometimes occur in non-surgical POI, but no intervention has been reliably shown to increase ovarian activity and natural conception rates.[1]
For women with POI, current guidance recommends hormone therapy until the usual age of menopause for prevention of morbidity and mortality, unless individual factors require another approach.[1]
Oocyte donation is an established option after POI. This is different from an investigational attempt to change ovarian function and should be discussed separately.[1]
AMH and AFC can help predict expected oocyte yield, but age remains a much stronger predictor of reproductive success than ovarian-reserve markers alone.[3]
Current guidance recommends DXA at diagnosis where available, lipid and diabetes screening at diagnosis, and at least annual review of blood pressure, weight and smoking status.[1]
We provide medical information support and Japan medical coordination. We can organize records, clarify published evidence, prepare questions, coordinate appointments and support medical interpretation. Diagnosis and treatment decisions stay with the treating physician.
We identify the dates and results that matter most so you are not sending an unreadable mix of screenshots, old reports and repeated tests.
We compare the diagnosis, cell source, route and outcome used in published studies with the information you have received, without promising a result.
We help coordinate appointments, organize the questions you want answered and support interpretation so you understand what is included before you travel or commit.
You do not need to decide first. Send the information you already have and start by identifying what is missing.
Send What I HaveA short, dated record set works better than sending every report you’ve ever received.
WhatsApp: +81-8070161366 LINE: +81-8075357788
No. Human studies have reported signals such as hormone changes, menstrual return and pregnancies, but current international POI guidance states that no intervention has been reliably shown to increase ovarian activity and natural conception rates. Protocols are still heterogeneous and investigational. [1]
There is no validated universal percentage. The 2025 review combined 27 studies and 694 patients, with most studies lacking control groups and using different diagnoses, cell sources and endpoints. Use live birth or another clearly defined endpoint rather than a marketing percentage based on AMH or AFC change. [5]
Yes. AMH is mainly a marker of the follicular pool and expected ovarian response. ASRM notes that AMH and AFC predict oocyte yield better than pregnancy or live birth, and age remains more important for reproductive success. [3]
Current guidance recommends chromosomal analysis and FMR1 premutation testing for non-iatrogenic POI. If the cause is unknown, 21-hydroxylase autoantibodies should be checked. TSH, bone density and cardiovascular risk also need attention because POI affects more than fertility. [1]
Do not make that decision from online material alone. For POI, guideline-supported care addresses low-estrogen symptoms and long-term bone, cardiovascular and other health risks. Fertility options should be discussed in parallel so an experimental approach does not unintentionally delay time-sensitive care. [1]
Ask for the exact diagnosis being treated, cell source and dose, processing method, administration route, regulatory status, written risks, total itemized price, follow-up schedule, outcome definition, published evidence for patients like you, cancellation terms and what happens if the procedure cannot go ahead.
Send your basic details, recent results and the questions you want answered. We can help organize the information and coordinate the next steps in Japan.
WhatsApp: +81-8070161366. LINE: +81-8075357788.
This page is educational—it doesn’t diagnose a condition, prescribe treatment, guarantee an outcome or replace care from a qualified physician. The cellular approaches described here are still investigational for ovarian indications.
